NCT06533878View on ClinicalTrials.gov

Evaluate Tolerability and Safety of HY209 in Healthy Volunteers

PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 13, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Dementia
Interventions
DRUG

HY-209

Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg, and white for 10 mg

DRUG

HY-209 placebo

Enteric coated tablet in the following colors: pink for 100 mg and yellow for 50 mg

Trial Locations (1)

Unknown

Kukjeon Pharmaceutical Co., Ltd., Anyang-si

Sponsors
All Listed Sponsors
lead

Kukjeon Pharmaceutical Co.,Ltd.

INDUSTRY